Currently Viewing:
Evidence-Based Oncology Patient-Centered Oncology Care: Real-World Perspectives 2013
The Angelina Effect: Rising Interest in Genetic Testing Creates Opportunities for Patients-and Profit
Ellen T. Matloff, MS
Faculty Index
Person-Centered Care: The New Business Case for Cancer
Amy Berman, BS, RN
Will Shifts in Oncology Outpatient Points of Care Lead to More Profits or Savings?
Peter B. Bach, MD, MAPP
Care Reflects Patient Choice, but Having the Data Reflect 'Consumerism' Is Another Matter
Cliff Goodman, PhD; Amy Berman, BS, RN; Dennis Scanlon, PhD; and Manasi A. Tirodkar, PhD, MS,
When Making Decisions in Cancer Care, Patients Want to Know: How Will I Feel?
Ethan Basch, MD
Cancer Patients Need Better Information, and Payers Should Demand They Receive It
Cliff Goodman, PhD; A. Mark Fendrick, MD; John L. Fox, MD, MHA; and Ira M. Klein, MD, MBA, FACP
Measures That Improve Quality Must Be Nimble if Imperfect, UnitedHealthcare's Newcomer Explains
Lee N. Newcomer, MD, MHA
With Data, Access and Sharing Are Keys to Improving Quality
Lee N. Newcomer, MD, MHA; Phyllis Torda; Dennis Scanlon, PhD; Ira M. Klein, MD, MBA, FACP
Can Clinical Pathways Change the 'Culture' in Cancer Care?
Bruce A. Feinberg, DO
Currently Reading
Payer Perspectives in Genetic Counseling
Karen Lewis, MS, MM, CGC
The Present-and Future-of Genetic Profiling in Oncology
Jerry Conway
Next-Generation Sequencing in Oncology: Are We Ready for Prime Time?
Lee N. Newcomer, MD, MHA; Michael A. Kolodziej, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP
Putting the 'Economics' Back Into Health Economics Outcomes Research
Scott D. Ramsey, MD, PhD
Value-Based Pricing: The Role of Outcomes Data in Pricing Models
Michael E. Chernew, PhD; Cliff Goodman, PhD; Jeffrey D. Dunn, PharmD, MBA; Kirby Eng, RPh
Redefining the Role of Industry in Contemporary Healthcare
John L. Fox, MD, MHA; Bo Gamble; and Cliff Goodman, PhD

Payer Perspectives in Genetic Counseling

Karen Lewis, MS, MM, CGC
Precision Medicine, examined how care targeted at the individual can hold down costs while improving quality. This includes matching the right drug to the right patient, and genetic testing is a tool for doing that.
Session 3, Precision Medicine, examined how care targeted at the individual can hold down costs while improving quality. This includes matching the right drug to the right patient, and genetic testing is a tool for doing that. But ordering the wrong test can be as harmful as no testing. That’s where genetic counselors can help. Karen Lewis, MS, MM, CGC, a medical policy and technology administrator and genetic counselor at Priority Health of Michigan, discussed the challenges and opportunities for genetic counseling and testing in oncology.
Done well, genetic counseling and testing fulfills the mission of the triple aim: better care, better population health, and lower costs. But doing it well requires understanding what tests should and should not be done, for cost and other reasons. Karen Lewis, MS, MM, CGC, began by noting that while genetic tests can be expensive, their costs are miniscule when compared with giving cancer patients a $10,000-a-month therapy that will not work.

Payers who seek help from genetic counselors must realize that the field of certified counselors is fairly small—there are only about 3000 in the United States and only 25 training programs. Payers should look for candidates with a master’s degree and board certification from the American Board of Genetic Counseling.

To deal with the rising need for its services, Lewis said, “The field has transformed itself from a face-to-face, brick-and-mortar type of service to a telephonic, telemedicine-based service.” Counselors themselves have studied whether this approach meets patient needs, “and they have seen some very positive outcomes.”

At its heart, Lewis said, “Genetic counseling is a communication process.” It combines the hard science of looking at test results and data with the social science of working with patients and families, and educating the family about what results mean.

So what is the role of a genetic counselor at a health plan? Lewis works with medical directors, developing policies on counseling and testing, reviewing requests for tests to ensure they make sense, and hearing grievances, which, ironically, is one of the best parts of her job. “It’s those outlier cases that bring to our attention things we might have missed during the normal processing,” she said. Change comes from those outliers, she said.

Genetic counselors can help a health plan bring order to a realm where tremendous opportunities for profit can lead to poor, uninformed choices by doctors and patients—especially as testing
incidents make their way into the media. Lewis was a counselor for 15 years before joining Priority Health, and she is alarmed when she sees the names of labs popping up that she’s never heard of. “It’s frightening—it’s important to choose a lab where you know you’re going to get a result that’s clinically valid.”

“The time has passed when we can just order from the most convenient lab,” she said later. “We need high-quality labs, but we also need the best price and high quality together.”

Inundated by heavy marketing, patients often demand the wrong test, or use home test kits that produce results they cannot interpret. “A mutation does not always necessarily lead to cancer, and we need to consider what else is going on,” she said. That’s why insurers are moving toward controlling when tests are ordered and encouraging counseling. Despite what some may think, the family practitioner may be ill equipped to order, much less interpret, genetic testresults (Table).

Data show high incidence of the wrong test being ordered, or of full tests being ordered even after a mutation has already been identified in the family. “Seventy-two percent of non-genetics-trained MDs rate themselves as having fair to poor knowledge regarding genetics,” Lewis said.

Top issues for payers, she said, include informed consent, transparency, and better coding. And ensuring access. “You’re going to have to partner, most likely, with a telephonic genetic service to get full coverage.” EBO
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!